Viking Therapeutics, Inc

Viking Therapeutics trades with a striking 21.08% short float—nearly double typical pharma levels—yet RSI sits at a neutral 42.4, suggesting no imminent capitulation. The $3.6B market cap biotech lacks earnings (hence no P/E), meaning valuation hinges entirely on pipeline conviction. This elevated short interest combined with moderate momentum creates squeeze potential if positive trial data materializes, but also signals meaningful skepticism among sophisticated traders about near-term catalysts or clinical risk. The stock sits removed from its 52-week high, giving bears room to push lower if sentiment deteriorates further.